SECsense Logo

Oncolytics Biotech Inc. Form 6-K Report: December 2024 Insights

$ONCY
Form 6-K
Filed on: 2024-12-23
Source
Oncolytics Biotech Inc. Form 6-K Report: December 2024 Insights

Here are the key insights extracted from the provided financial report (Form 6-K) for Oncolytics Biotech Inc.:

  1. Filing Details:
  • Type of Filing: Form 6-K
  • Commission File Number: 001-38512
  • Date of Filing: December 23, 2024
  • Reporting Period: December 2024
  1. Company Information:
  • Registrant Name: Oncolytics Biotech Inc.
  • Address: Suite 804, 322 11th Avenue SW, Calgary, Alberta, Canada T2R 0C5
  1. Submission Indications:
  • The registrant is confirming its filing status under either Form 20-F or Form 40-F, indicating that it files annual reports.
  • The filing indicates that Form 40-F is selected (as per checkmark representation).
  1. Regulatory Compliance:
  • The report includes notes related to Regulation S-T, outlining the conditions under which Form 6-K may be submitted in paper format.
  • The report is submitted by a foreign private issuer and complies with the Securities Exchange Act of 1934.
  1. Signature:
  • The document is signed by Kirk Look, who is identified as the Chief Financial Officer of Oncolytics Biotech Inc.
  1. Exhibits:
  • The filing includes Exhibit 99.1, which is referenced as a Press Release. This may contain additional information relevant to the financial report or recent developments concerning the company.

This summary captures the essential elements of the filing, highlighting compliance with SEC regulations and providing a clear view of the company's reporting responsibilities and corporate identity.